These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35481270)

  • 41. Nitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats.
    Yu Z; Xu X; Xiang Z; Zhou J; Zhang Z; Hu C; He C
    PLoS One; 2010 Apr; 5(4):e9956. PubMed ID: 20386702
    [TBL] [Abstract][Full Text] [Related]  

  • 42. REST Protects Dopaminergic Neurons from Mitochondrial and α-Synuclein Oligomer Pathology in an Alpha Synuclein Overexpressing BAC-Transgenic Mouse Model.
    Ryan BJ; Bengoa-Vergniory N; Williamson M; Kirkiz E; Roberts R; Corda G; Sloan M; Saqlain S; Cherubini M; Poppinga J; Bogtofte H; Cioroch M; Hester S; Wade-Martins R
    J Neurosci; 2021 Apr; 41(16):3731-3746. PubMed ID: 33563726
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease.
    Gründemann J; Schlaudraff F; Haeckel O; Liss B
    Nucleic Acids Res; 2008 Apr; 36(7):e38. PubMed ID: 18332041
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.
    Hayashita-Kinoh H; Yamada M; Yokota T; Mizuno Y; Mochizuki H
    Biochem Biophys Res Commun; 2006 Mar; 341(4):1088-95. PubMed ID: 16460685
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effect of benzo(a)pyrene on dopaminergic neurons and α-synuclein in brain and its mechanism involved].
    Qi YZ; Quan HH; Xu WX; Li QR; Zhou H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Jun; 52(3):438-443. PubMed ID: 32541975
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dieldrin induces ubiquitin-proteasome dysfunction in alpha-synuclein overexpressing dopaminergic neuronal cells and enhances susceptibility to apoptotic cell death.
    Sun F; Anantharam V; Latchoumycandane C; Kanthasamy A; Kanthasamy AG
    J Pharmacol Exp Ther; 2005 Oct; 315(1):69-79. PubMed ID: 15987830
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oxidative stress-induced posttranslational modifications of alpha-synuclein: specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity.
    Xiang W; Schlachetzki JC; Helling S; Bussmann JC; Berlinghof M; Schäffer TE; Marcus K; Winkler J; Klucken J; Becker CM
    Mol Cell Neurosci; 2013 May; 54():71-83. PubMed ID: 23369945
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra.
    Moran LB; Croisier E; Duke DC; Kalaitzakis ME; Roncaroli F; Deprez M; Dexter DT; Pearce RK; Graeber MB
    Acta Neuropathol; 2007 Mar; 113(3):253-63. PubMed ID: 17203291
    [TBL] [Abstract][Full Text] [Related]  

  • 49. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease.
    Zhang Y; Wu Q; Zhang L; Wang Q; Yang Z; Liu J; Feng L
    Pharmacol Res; 2019 Dec; 150():104538. PubMed ID: 31707034
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 7,8-dihydroxyflavone Ameliorates Motor Deficits Via Suppressing α-synuclein Expression and Oxidative Stress in the MPTP-induced Mouse Model of Parkinson's Disease.
    Li XH; Dai CF; Chen L; Zhou WT; Han HL; Dong ZF
    CNS Neurosci Ther; 2016 Jul; 22(7):617-24. PubMed ID: 27079181
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular Signatures of Neuroinflammation Induced by αSynuclein Aggregates in Microglial Cells.
    Sarkar S; Dammer EB; Malovic E; Olsen AL; Raza SA; Gao T; Xiao H; Oliver DL; Duong D; Joers V; Seyfried N; Huang M; Kukar T; Tansey MG; Kanthasamy AG; Rangaraju S
    Front Immunol; 2020; 11():33. PubMed ID: 32082315
    [TBL] [Abstract][Full Text] [Related]  

  • 53. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
    Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
    Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Down-regulation of natural resistance-associated macrophage protein-1 (Nramp1) is associated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)/1-methyl-4-phenylpyridinium (MPP
    Wu KC; Liou HH; Lee CY; Lin CJ
    Neuropathol Appl Neurobiol; 2019 Feb; 45(2):157-173. PubMed ID: 29679389
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease.
    Lotharius J; Brundin P
    Hum Mol Genet; 2002 Oct; 11(20):2395-407. PubMed ID: 12351575
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Modelling cognitive deficits in Parkinson's disease: Is CA2 a gateway for hippocampal synucleinopathy?
    Cinar E; Yalcin-Cakmakli G; Saka E; Ulusoy A; Yuruker S; Elibol B; Tel BC
    Exp Neurol; 2020 Aug; 330():113357. PubMed ID: 32437708
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Geniposide reduces α-synuclein by blocking microRNA-21/lysosome-associated membrane protein 2A interaction in Parkinson disease models.
    Su C; Yang X; Lou J
    Brain Res; 2016 Aug; 1644():98-106. PubMed ID: 27173998
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Explorative Combined Lipid and Transcriptomic Profiling of Substantia Nigra and Putamen in Parkinson's Disease.
    Xicoy H; Brouwers JF; Wieringa B; Martens GJM
    Cells; 2020 Aug; 9(9):. PubMed ID: 32858884
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson's disease mice.
    Karikari AA; McFleder RL; Ribechini E; Blum R; Bruttel V; Knorr S; Gehmeyr M; Volkmann J; Brotchie JM; Ahsan F; Haack B; Monoranu CM; Keber U; Yeghiazaryan R; Pagenstecher A; Heckel T; Bischler T; Wischhusen J; Koprich JB; Lutz MB; Ip CW
    Brain Behav Immun; 2022 Mar; 101():194-210. PubMed ID: 35032575
    [TBL] [Abstract][Full Text] [Related]  

  • 60. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
    Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.